

PMCPA

Prescription Medicines
Code of Practice Authority

Global Code Update Roundtable

UK Update

**Latin American Pharmaceutical Compliance
Congress and Best Practices Forum**

Tuesday 29 July 2014

Heather Simmonds

Director

Prescription Medicines Code of Practice Authority

www.pmcpa.org.uk

Prescription Medicines Code of Practice Authority

Heather Simmonds, Director

Etta Logan, Deputy Director

Jane Landles, Secretary

Tannyth Cox, Deputy Secretary

Appointed by and reports to ABPI Board of Management.

ROLE:

Responsible for administration of the Code and complaints procedure including provision of advice, guidance and training.

Arranging conciliation.

RECREATED FROM AN ORIGINAL COPY

Confidential

Not for Publication

**CODE OF
SALES PROMOTION PRACTICE
FOR
MEDICAL SPECIALITIES
IN THE UNITED KINGDOM**

October, 1958

**THE ASSOCIATION OF BRITISH PHARMACEUTICAL
INDUSTRY**

**Tavistock House South
Tavistock Square
London W.C.1
EUSton 2531/3**



CODE OF PRACTICE
for the
PHARMACEUTICAL
INDUSTRY

2014

PMICPA

Prescription Medicines
Code of Practice Authority


History of UK Disclosure of Certain Payments


Aggregate disclosure introduced in 2011 ABPI Code for disclosure of certain 2012 payments.

Additional requirements for 2013 payments.

2014 ABPI Code included implementation of most of the EFPIA Disclosure Code (payments in 2015, disclosure in 2016)

ANNUALLY FROM:	2013	2014	2015	2016	NOTES
Clause 18.5 Payments made in connection with joint working			Collect financial amount/value and name of recipient	Disclose by 30 June the previous year's data regardless of whether the value is transferred to healthcare organisation or some other funding model is used	Refer to notes for Clause 21 below. Executive summary must be published before arrangements are implemented.
Clause 18.6 Donations/grants/benefits in kind to institutions, organisations, associations which are comprised of health professionals and/or provide healthcare or conduct research	Disclose within 3 calendar months of the end of the company's financial year, details of donations and grants made in the previous year, to include financial amount/value and the name of recipient organisation. All reasonable steps should be taken to collect data from overseas affiliates etc		Collect details of benefits in kind in addition to grants and donations	Disclose details of grants, donations and benefits in kind by 30 June each year. Fees and expenses should be disclosed separately.	Refer to notes for Clause 21 below. Companies are encouraged to ask recipients to make such funding public.
Clause 18.7 Fees for service paid to institutions, organisations, associations for services or any other type of funding by companies not otherwise covered by the Code			Collect data including financial amount/value and recipient institution, organisation or association	Disclose details by 30 June. Fees and expenses should be disclosed separately.	Refer to notes for Clause 21 below.
Clause 19.4 Sponsorship of health professionals or administrative staff to attend 3rd party meetings	Disclose within 3 calendar months of the end of the company's financial year total aggregate amount paid in the previous year for registration fees (whether paid by UK company or overseas affiliate etc), accommodation and overseas travel, the total number of recipients and the total number of attendances. Include best estimate of accommodation and travel costs paid by overseas affiliates etc		Disclose 2014 data according to second 2012 Edition of the Code. Collect 2015 data according to Clause 19.5 of 2014 Code (see below)	Go to Clause 19.5 of 2014 Code.	Refer to notes for Clause 21 below. In 2015 the requirements change such that from then on data will have to be collected for all meetings and each recipient named.

 See Second Edition of 2012 Code for details

 See 2014 Code for details

NB. The term 'overseas affiliates etc' includes overseas affiliates, head offices in the UK or overseas and UK based European offices

Proposals for the 2015 ABPI Code include:

Method of disclosure

central platform, UK template

ABPI Board Review

Usual update

What else has the PMCPA been working on?

Recent cases on disclosure of clinical trial results

Stakeholder engagement

Communications

Thank you